Tuesday, April 25, 2017 2:39:13 PM
kabunushi,
Making that kind of statement in January 2016 with a known futility rec in their pockets would be legal quicksand to stand on since Cognate, through Linda, would be in on this type of deception and be lost to lawsuits too.
The numbers we have pretty much confirm the trial is close to demonstrating absolute success. The bear argument says 60% of events (.6×348=209) happened in July 2015 and yet 233 OS events have not happened close to 2 years later even when we know that survival seldom goes beyond 11-13 months past progression. At the rate that ramp up was occurring in late 2014 and 2015 the OS difference between 209 and 233 would have been made up for in about 3/4 months. That would take us to 16/17 months from July 2015 which was November/December 2016. Still we have not reached 233 OS events as of almost May 2017. OS doesn't lie so the focus by bears stays on PFS. Best wishes.
Making that kind of statement in January 2016 with a known futility rec in their pockets would be legal quicksand to stand on since Cognate, through Linda, would be in on this type of deception and be lost to lawsuits too.
The numbers we have pretty much confirm the trial is close to demonstrating absolute success. The bear argument says 60% of events (.6×348=209) happened in July 2015 and yet 233 OS events have not happened close to 2 years later even when we know that survival seldom goes beyond 11-13 months past progression. At the rate that ramp up was occurring in late 2014 and 2015 the OS difference between 209 and 233 would have been made up for in about 3/4 months. That would take us to 16/17 months from July 2015 which was November/December 2016. Still we have not reached 233 OS events as of almost May 2017. OS doesn't lie so the focus by bears stays on PFS. Best wishes.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
